SIST EN ISO 10993-7:2026

Overview

SIST EN ISO 10993-7:2026 outlines requirements for the biological evaluation of medical devices, specifically addressing the management of residual ethylene oxide (EO) and ethylene chlorohydrin (ECH) in sterilized products. Issued by the Slovenian Institute for Standardization (SIST), this standard serves as a key reference for manufacturers, regulatory bodies, and testing laboratories when ensuring the safety of EO-sterilized medical devices. It includes methods for measuring EO and ECH residuals, defines allowable limits, and describes processes for determining compliance before device release. The guidance supports the risk management of chemical residuals to limit patient and user exposure, aligning with internationally recognized best practices and regulatory requirements.

Key Topics

• Allowable Limits (AL): Specifies maximum levels for EO and ECH residuals on medical devices, based on exposure duration and patient population.
• Device Categorization: Defines exposure categories-limited (<24 hours), prolonged (24 hours to 30 days), and long-term (>30 days) contact-to set appropriate residual limits.
• Measurement Procedures: Details validated sampling, extraction, and analytical methods for detecting and quantifying EO and ECH.
• Compliance Determination: Outlines conformity assessment methods and release procedures, including batch release and use of residual dissipation curves.
• Risk-Based Approach: Allows alternative limits through documented toxicological risk assessment by considering device usage scenarios and intended patient groups.
• Annex Guidance: Provides supporting information, examples, and flowcharts for practical implementation of the standard.

Applications

SIST EN ISO 10993-7:2026 is intended for use in the design, manufacturing, and regulatory approval of EO-sterilized medical devices that contact patients or users. Applications include:

• Medical Device Manufacturing: Ensures new and existing products meet safety requirements per EO/ECH residual limits before market release.
• Sterilization Process Validation: Guides sterilization cycle development and routine control, helping manufacturers optimize parameters such as EO concentration, dwell time, and aeration.
• Risk Assessment: Supports preparation of documentation for regulatory submissions by justifying residual levels through risk assessments that reflect product design and intended use.
• Product Release Decisions: Assists in batch release and routine monitoring, verifying that device residuals are within acceptable limits at the point of distribution.
• Process Optimization: Enables manufacturers to select and qualify safer materials or alternative sterilization methods, reducing residual chemical exposure risk to patients.

Devices with no direct or indirect body or user contact, such as certain in vitro diagnostic devices, and those made solely from materials not retaining EO or ECH (e.g., glass or metal), are out of scope.

Related Standards

For comprehensive compliance and process integration, consider the following related international standards:

• ISO 10993-1: Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process
• ISO 11135: Sterilization of health care products – Ethylene oxide – Requirements for the development, validation, and routine control of a sterilization process
• ISO 10993-17: Biological evaluation of medical devices – Part 17: Toxicological risk assessment of medical device constituents
• ISO 10993-23: Biological evaluation of medical devices – Part 23: Tests for irritation

By adhering to SIST EN ISO 10993-7:2026, manufacturers can demonstrate effective control of EO and ECH residuals, enhance patient safety, and ensure regulatory compliance in accordance with international biological evaluation standards for medical devices.